(Q39442878)

12 September 2017

title

NMIBC risk calculators: how useful are they for the practicing urologist and how can their clinical utility be improved? (English)

1 reference

12 September 2017

Rianne J M Lammers

1

1 reference

12 September 2017

Richard J Sylvester

series ordinal

2

1 reference

12 September 2017

Cheryl T Lee

series ordinal

3

1 reference

12 September 2017

J Alfred Witjes

series ordinal

4

1 reference

12 September 2017

publication date

11 February 2013

1 reference

Urologic Clinics of North America

12 September 2017

published in

1 reference

12 September 2017

volume

40

1 reference

12 September 2017

issue

2

1 reference

12 September 2017

page(s)

155-164

1 reference

Epidemiology and genetic susceptibility to bladder cancer

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

7 January 2021

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Mechanisms of disease: The epidemiology of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Bladder cancer: epidemiology, staging and grading, and diagnosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

How well can you actually predict which non-muscle-invasive bladder cancer patients will progress?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Risk group stratification to predict recurrence after transurethral resection in Japanese patients with stage Ta and T1 bladder tumours: validation study on the European Association of Urology guidelines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical bacillus calmette-guerin instillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Molecular Grade (FGFR3/MIB-1) and EORTC Risk Scores Are Predictive in Primary Non–Muscle-Invasive Bladder Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Do standardised prognostic algorithms reflect local practice? Application of EORTC risk tables for non-muscle invasive (pTa/pT1) bladder cancer recurrence and progression in a local cohort.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Nomograms for prediction of disease recurrence in patients with primary Ta, T1 transitional cell carcinoma of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

A pretreatment nomogram predicting recurrence- and progression-free survival for nonmuscle invasive bladder cancer in Japanese patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Predicting the risk of high-grade bladder cancer using noninvasive data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Evaluating the utility of a preoperative nomogram for predicting 90-day mortality following radical cystectomy for bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Natural history, recurrence, and progression in superficial bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Compliance with guidelines for patients with bladder cancer: variation in the delivery of care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Heuristics and biases: selected errors in clinical reasoning.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Predicting Nonsentinel Node Status After Positive Sentinel Lymph Biopsy for Breast Cancer: Clinicians Versus Nomogram

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Prognosis of Muscle-Invasive Bladder Cancer: Difference between Primary and Progressive Tumours and Implications for Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Delays in diagnosis and bladder cancer mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Use of restaging bladder tumor resection for bladder cancer among Medicare beneficiaries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Nomograms for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Combining a molecular profile with a clinical and pathological profile: biostatistical considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2013.01.002

10.1016/J.UCL.2013.01.002

7 January 2021

Identifiers

DOI

1 reference

12 September 2017

1 reference